CN1972668A - 含三萜的成油凝胶剂、含三萜的油凝胶和制备含三萜的油凝胶的方法 - Google Patents
含三萜的成油凝胶剂、含三萜的油凝胶和制备含三萜的油凝胶的方法 Download PDFInfo
- Publication number
- CN1972668A CN1972668A CNA2005800207877A CN200580020787A CN1972668A CN 1972668 A CN1972668 A CN 1972668A CN A2005800207877 A CNA2005800207877 A CN A2005800207877A CN 200580020787 A CN200580020787 A CN 200580020787A CN 1972668 A CN1972668 A CN 1972668A
- Authority
- CN
- China
- Prior art keywords
- oleogel
- weight
- forming agent
- triterpene
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003648 triterpenes Chemical class 0.000 title claims abstract description 62
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000007788 liquid Substances 0.000 claims abstract description 23
- 239000003795 chemical substances by application Substances 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 21
- 239000006185 dispersion Substances 0.000 claims description 19
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 claims description 13
- 239000003921 oil Substances 0.000 claims description 11
- 235000019198 oils Nutrition 0.000 claims description 11
- 241000196324 Embryophyta Species 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 9
- 239000012188 paraffin wax Substances 0.000 claims description 5
- 238000005054 agglomeration Methods 0.000 claims description 4
- 230000002776 aggregation Effects 0.000 claims description 4
- 239000001993 wax Substances 0.000 claims description 4
- 235000019489 Almond oil Nutrition 0.000 claims description 3
- 244000025272 Persea americana Species 0.000 claims description 3
- 235000008673 Persea americana Nutrition 0.000 claims description 3
- 239000008168 almond oil Substances 0.000 claims description 3
- 239000004006 olive oil Substances 0.000 claims description 3
- 235000008390 olive oil Nutrition 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 239000002562 thickening agent Substances 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 239000008158 vegetable oil Substances 0.000 claims description 3
- 239000010775 animal oil Substances 0.000 claims 2
- 235000010446 mineral oil Nutrition 0.000 claims 1
- 239000002480 mineral oil Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 description 39
- 239000000843 powder Substances 0.000 description 16
- 235000019580 granularity Nutrition 0.000 description 9
- 238000002425 crystallisation Methods 0.000 description 6
- 230000008025 crystallization Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 4
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 4
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 4
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 4
- 239000000084 colloidal system Substances 0.000 description 4
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- MQYXUWHLBZFQQO-QGTGJCAVSA-N lupeol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C MQYXUWHLBZFQQO-QGTGJCAVSA-N 0.000 description 4
- PKGKOZOYXQMJNG-UHFFFAOYSA-N lupeol Natural products CC(=C)C1CC2C(C)(CCC3C4(C)CCC5C(C)(C)C(O)CCC5(C)C4CCC23C)C1 PKGKOZOYXQMJNG-UHFFFAOYSA-N 0.000 description 4
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 3
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 3
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000002398 materia medica Substances 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 229940100243 oleanolic acid Drugs 0.000 description 3
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 125000003179 lupane group Chemical group 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000003973 paint Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 230000009974 thixotropic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- BZNIIOGSANMIET-JEKRXEKZSA-N Allobetulin Natural products O[C@@H]1C(C)(C)[C@H]2[C@](C)([C@@H]3[C@](C)([C@@]4(C)[C@@H]([C@H]5[C@H]6C(C)(C)CC[C@]5(CO6)CC4)CC3)CC2)CC1 BZNIIOGSANMIET-JEKRXEKZSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- JYDNKGUBLIKNAM-UHFFFAOYSA-N Oxyallobutulin Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C(=C)C)C5C4CCC3C21C JYDNKGUBLIKNAM-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- BZNIIOGSANMIET-UHFFFAOYSA-N allobetuline Natural products CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3)(C)C2CCC1C1C2OCC13CCC2(C)C BZNIIOGSANMIET-UHFFFAOYSA-N 0.000 description 1
- BZNIIOGSANMIET-HWNNWUPFSA-N allobetulinol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC[C@]([C@]1(C)CC3)(C)[C@@H]2CC[C@@H]1[C@H]1[C@H]2OC[C@]13CCC2(C)C BZNIIOGSANMIET-HWNNWUPFSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- MVIRREHRVZLANQ-UHFFFAOYSA-N betulin Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5C(CCC5(CO)CCC34C)C(=C)C)C1(C)C MVIRREHRVZLANQ-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003535 tetraterpenes Chemical class 0.000 description 1
- 235000009657 tetraterpenes Nutrition 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C35/22—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system
- C07C35/37—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with a hydroxy group on a condensed system having three rings
- C07C35/42—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with a hydroxy group on a condensed system having three rings derived from the phenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compounds Of Unknown Constitution (AREA)
- Colloid Chemistry (AREA)
- Measuring Volume Flow (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
本发明涉及成油凝胶剂,其含有至少一种高度分散的三萜。本发明还涉及油凝胶,其包含非极性液体和含高度分散的三萜的成油凝胶剂,所述非极性液体的含量基于凝胶总重量为80重量%至99重量%,所述含高度分散的三萜的成油凝胶剂的含量基于凝胶总重量为1重量%至20重量%。本发明还涉及制备油凝胶的方法。
Description
本发明涉及成油凝胶剂、具有该成凝胶剂的油凝胶和制备油凝胶的方法。
凝胶是由液相和固相构成的精细分散的体系,其中固相形成相连的三维支架,并且液相与固相这两相完全互相渗透。基本上将凝胶分成亲水性凝胶和疏水性凝胶。疏水性凝胶也称为油凝胶。油凝胶基于非极性液体(Flüssigkeit)例如油、蜡或石蜡(Paraffin),在其中加入了用于获得所希望的物理特性的成凝胶剂。
根据其组成,这样的油凝胶可以用于各种不同的目的。
特别是在药物领域中,油凝胶可用于局部应用。在药物油凝胶中,除了药物活性物质之外,在凝胶中还存在成凝胶剂。一种通常用于药物油凝胶的成凝胶剂是高度分散的二氧化硅,其可以以商品名Aerosil而获得。油凝胶具有显著的触变性,即其在机械作用下液化并随后再次固化。其他凝胶,例如含有果胶作为成凝胶剂的凝胶,在酸作用下交联,还有另外一些凝胶根据温度发生胶凝作用,例如明胶。
油凝胶还可用于工程技术领域。对此可提及的例子是非极性的涂覆剂(Auftragsmittel)(不流挂的涂料(tropffreie Farben))。对于此用途,也可以将高度分散的二氧化硅用作成凝胶剂。这种矿物性成凝胶剂对于工程技术应用来说具有缺点,即在对用这样的油凝胶处理过的产品进行热运用时,所述成凝胶剂不能无灰分地燃烧。
本发明的任务是提供本身是药物学上活性的并能无灰分地燃烧的成油凝胶剂,具有这样的成凝胶剂的油凝胶,和制备具有这样的成凝胶剂的油凝胶的方法。
该任务通过具有权利要求1的特征的成油凝胶剂、具有权利要求11的特征的油凝胶和具有权利要求17的特征的方法而得以完成。
根据本发明,所述成油凝胶剂具有至少一种高度分散的三萜。
三萜,例如桦木脑、羽扇醇、桦木酸、齐墩果酸和类似的化合物,是正在发展中的原料,其存在于例如桦树皮中。在此,桦木脑、桦木酸、羽扇醇和齐墩果酸是五环三萜,前三个具有羽扇烷骨架,最后一个具有齐墩果烷骨架。羽扇烷基团的特有的特征是在五环系统内的具有5个碳原子的环,其在位置C-19处具有α-异戊烯基基团。
从植物组成部分中获得三萜的方法,特别是从桦树皮中获得桦木脑的方法,例如描述在WO 2001/72315 A1或WO 2004/016336 A1中。
三萜特别是桦木脑的药理学特性使得本发明的含三萜的成油凝胶剂用于制备美容和药物用油凝胶是特别引人注目的。
早在1899年就已经证实了桦木脑的防腐特性,因此其用于伤口绷带和膏药的消毒(Wheeler,J.,(1899),Pharm.J.,Die Darstellungdes Betulin durch Sublimation,494,Ref.Chem.Centr.1900 I,S.353)。
此外,对于桦木脑和桦木脑衍生物,还检测到抑制炎症的、类似可的松的作用,同样在体外使用不同的肿瘤细胞系时检测到抑制细胞作用(Carmen Recio,M.,等人,(1995),Investigations on thesteroidal anti-inflammatory activity of triterpenoids fromDiospyros leucomelas,Planta Med.61,S.9-12;Yasukawa,K.,等人,(1991),Sterol and triterpene derivates from plants,Oncogene 48,S.72-76)。
桦木脑对于单纯疱疹病毒的抗病毒作用描述于US 5,750,578中。US 2002/0119935 A1描述了在细菌感染时三萜的作用,和US2002/0128210 A1描述了在真菌感染时三萜的作用。
在成油凝胶剂中至少一种三萜的平均粒度优选小于50μm。特别优选地,平均粒度小于10μm或者甚至小于100nm,以便获得优异的成凝胶特性。在本文中,如果粒度为100nm至10μm,那么称之为具有精细分散度,和如果粒度为1nm至100nm,那么称之为具有胶体分散度。
在成油凝胶剂中至少一种三萜的二次附聚体的含量优选小于20重量%。理想地,存在均匀的粒度分布,因而单个粒度的频数(Hufigkeit)具有正态分布。因为二次附聚体的存在可能会对粉末的成凝胶特性产生不利的影响,如文章Knop,Reimann:“KolloidaleKieselsuren als Gelbildner”,GO-VI-Verlag,2001所推测的。
对于作为成油凝胶剂的至少一种高度分散的三萜的特性产生影响,还可以包括三萜的比表面积,其中试验表明,随着比表面积的增加,成凝胶特性得到改善。在一种布置中,至少一种三萜的比表面积为1m2/g至500m2/g,优选为10m2/g至100m2/g,和特别优选为20m2/g至50m2/g。
除了三萜例如桦木脑、桦木酸、羽扇醇或别桦木脑之外,以含三萜的微细化粉末形式存在的成油凝胶剂还可以包含一定含量的其他物质,例如在能够从中提取出三萜的含三萜的植物组成部分如桦树皮中同样也以某一含量天然存在的物质。在本发明的成油凝胶剂中三萜的含量优选大于80重量%,特别优选大于90重量%,基于成油凝胶剂的重量。有利地,基于三萜含量的桦木脑含量在此大于80重量%。
本发明的含三萜的成油凝胶剂还可用于工程技术用途,例如用在非极性涂覆剂中。它对于这种类型的用途来说具有优点,即其与矿物性成凝胶剂不同,它在进行热运用时能够无灰分地燃烧。
本发明的油凝胶含有:
-非极性液体,其含量基于凝胶总重量为80重量%至99重量%,和
-作为成凝胶剂的前述含三萜的成油凝胶剂,其含量基于凝胶总重量为1重量%至20重量%,优选3重量%至15重量%,特别优选6重量%至12重量%。
以油凝胶形式存在的这种半固体制剂的优点在于配方的简单化,其中三萜同时作为药物活性物质和成凝胶剂起作用,从而可以放弃附加的成凝胶剂。因此,所述油凝胶特别适合于具有过敏风险的皮肤。
因此,通过使用所述含三萜的、高度分散的(优选精细分散的或胶体分散的)粉末作为具有在所述浓度范围内的三萜含量并且具有指定的平均粒度的成油凝胶剂,能够制备一种凝胶,其除了药物学上活性的、以粉末形式存在的至少一种三萜和非极性液体之外必须不含有其他成分。三萜在非极性液体中具有小于0.5%的溶解度,从而三萜在该凝胶中主要以不溶的固体颗粒形式存在。
但是,不言而喻,也存在这样的可能性,即除了在成凝胶剂中存在的三萜之外,还向油凝胶添加了其他药物学活性物质。
具有含三萜的成油凝胶剂的油凝胶的优点根据应用领域是多种多样的。
因此,对于美容-药物领域,提供了一种新的半固体制剂,与含水的制剂不同,其在干燥的皮肤的情况下和在嘴唇上可以特别良好地使用。本发明油凝胶的局部应用在具有过敏风险的人中是特别有利的,因为不需要其他的成凝胶剂。另一方面,还使得可以使用没有添加剂的油凝胶作为药物学基质,在其中可以特别容易地混合入其他亲脂性活性物质或助剂,以及用水还可以特别容易地混合入亲水性活性物质或助剂。
对于工程技术领域,提供了一种触变的组合物,其具有非矿物性的、从而可无灰分地燃烧的成油凝胶剂。一种应用范围例如是非极性的涂覆剂(不流挂的涂料),其具有由于本发明的成油凝胶剂而得到提高的触变性。所述成凝胶剂同时具有了对于三萜来说已知的防腐特性和对于三萜来说已知的光保护作用。
在该油凝胶中,非极性液体的含量优选为88重量%至94重量%,和含三萜的粉末的含量优选为6重量%至12重量%。
对于该油凝胶,任意的非极性液体适合作为所述非极性液体,例如植物、动物或合成的油,蜡和石蜡。非极性液体例如为植物油,例如向日葵油、橄榄油、鳄梨油、杏仁油或这些油的混合物。
本发明的油凝胶具有非常小程度地依赖温度的粘度,但是具有突出的触变性能,由此可以简单地贮存和使用凝胶。
如果其在待增稠的液体中以低于胶凝极限值进行使用,也就是低于为了从液体和三萜形成油凝胶所需的浓度,那么以高度分散的(优选精细分散或胶体分散的)三萜粉末形式存在的成油凝胶剂还可以用作增稠剂。
因此,可能将高度分散的三萜以这样的浓度加入非极性液体中,所述浓度低于胶凝极限值,也就是低于对于凝胶形成所需的浓度。结果是得到一种油凝胶,也就是一种粘稠的制剂,其中高度分散的(优选精细分散或胶体分散的)三萜用作增稠剂。
下文中,将借助于实施例并参考所附附图来解释本发明。
附图在上部区域中以柱状图的形式显示了本发明的高度分散的成油凝胶剂样品的均匀粒度分布。作为该曲线的基础的测量值以表的形式描述在附图的下部区域中。在此,表的右边部分中的频数分布的值各自涉及两个粒度之间的间隙,所述两个粒度在表的左边部分中于所属的频数值之上和之下给出。因此,例如可从表中看出,在所研究的样品中大小为0.209μm至0.240μm的颗粒的含量为0.14%。
样品的粒度为0.2μm至60.2μm,大小分布的最大值为2.5μm至5μm。
所研究的样品的粒度分布几乎是均匀的,即分布的频数对于小于最大值(大约在3.5μm处)的直径来说是不断增加的,而对于大于最大值的直径来说是不断减小的。只是对于大小为大约34μm至45μm的颗粒来说,频数又再次有一定程度的增加。这一增加应当归因于二次附聚体,也就是颗粒的积聚物,其在真正的结晶过程之后才形成,或者其通过两个或更多个首先各自独立地结晶的晶体的一起生长而出现。
根据气相色谱法分析,该粉末含有85重量%的桦木脑、5重量%的桦木酸、3重量%的齐墩果酸、0.7重量%的羽扇醇和6.3重量%的其余三萜衍生物。
通过使用这些高度分散的粉末作为成凝胶剂来制备油凝胶,方法是将含量基于油凝胶总重量为9重量%的该粉末与向日葵油混合。结果是得到稳定的半固体凝胶,其具有十分显著的触变性。
这种如此产生的油凝胶适于在人类和动物中治疗各种各样的皮肤疾病。对此的实例为,人类中的光化性角化病和基底细胞癌,和哺乳动物中的乳房炎。
该用作成油凝胶剂的、含有至少一种三萜的粉末可以借助于任何常规的提取方法从植物组成部分中获得。如果通过这样的提取方法获得的粉末不具有对于成凝胶特性所必需的可分散性、平均粒度和均匀的粒度分布,那么可以将该粉末经历多种不同的方法以获得所希望的粒度、均匀度和可分散性。对此,本领域技术人员已知多种方法,其中的一些将在下文中作简短的说明。
当粉末中的粒度过大时,撞击或重力方法适合于将颗粒变小。
此外,还可以将该粉末溶解在合适的溶剂例如四氢呋喃中,然后重新进行结晶。该结晶过程例如可以通过饱和的溶剂的喷雾干燥和冷却来进行。在此,粒度可以通过结晶条件来调节。在喷雾干燥的情况下,结晶条件取决于例如通过其而喷射出三萜-溶剂混合物的喷嘴的直径,以及混合物所喷射入的腔室中的温度和压力。在通过冷却饱和溶液进行结晶的情况下,结晶条件取决于在冷却期间的时间温度梯度,以及溶液中的三萜浓度。
已经表明,通过下列方法可以获得具有大比表面积的特别小的三萜颗粒,即向饱和的三萜-溶剂混合物中搀混入冷的溶剂。搀混入冷的溶剂导致溶液冷却下来,由此三萜结晶出来。同时,所加入的冷的溶剂还降低了溶剂中的三萜浓度,结果是较早出现了小晶体,这对于成凝胶特性来说是有利的。
最后,还可能将存在的粉末进行分级,以便获得具有所希望的大小分布的粉末。
Claims (24)
1.成油凝胶剂,其特征在于,其含有至少一种高度分散的三萜。
2.根据权利要求1的成油凝胶剂,其中所述至少一种三萜的平均粒度小于50μm。
3.根据权利要求2的成油凝胶剂,其中所述至少一种三萜的平均粒度小于10μm。
4.根据前述权利要求中任一项的成油凝胶剂,其中所述至少一种三萜的二次附聚体的含量小于20重量%。
5.根据权利要求4的成油凝胶剂,其中所述至少一种三萜具有均匀的粒度分布。
6.根据前述权利要求中任一项的成油凝胶剂,其中所述至少一种三萜的比表面积为1m2/g至500m2/g。
7.根据权利要求6的成油凝胶剂,其中所述至少一种三萜的比表面积为10m2/g至100m2/g。
8.根据权刷要求7的成油凝胶剂,其中所述至少一种三萜的比表面积为20m2/g至50m2/g。
9.根据前述权利要求中任一项的成油凝胶剂,其中所述至少一种高度分散的三萜的含量大于80重量%。
10.根据权利要求9的成油凝胶剂,其中所述至少一种高度分散的三萜的含量大于90重量%。
11.根据前述权利要求中任一项的成油凝胶剂,其中所述至少一种三萜中的桦木脑含量大于80重量%。
12.油凝胶,其含有下列组分:
-非极性液体,其含量基于凝胶总重量为80重量%至99重量%,
-根据前述权利要求中任一项的成油凝胶剂,其含量基于凝胶总重量为1重量%至20重量%。
13.根据权利要求12的油凝胶,其中成油凝胶剂的含量为3重量%至15重量%。
14.根据权利要求13的油凝胶,其中非极性液体的含量为88重量%至94重量%,和成油凝胶剂的含量为6重量%至12重量%。
15.根据权利要求12-14中任一项的油凝胶,其中非极性液体是植物油、动物油、矿物油或合成油。
16.根据权利要求15的油凝胶,其中所述油是下列植物油中的一种或下列植物油的混合物:向日葵油、橄榄油、鳄梨油、杏仁油。
17.根据权利要求12-14中任一项的油凝胶,其中非极性液体是蜡或石蜡。
18.制备油凝胶的方法,所述油凝胶包含下列组分的混合物:
-非极性液体,其含量基于凝胶总重量为80重量%至99重量%,
-作为成凝胶剂的根据权利要求1-11中任一项的成油凝胶剂,其含量基于凝胶总重量为1重量%至20重量%。
19.根据权利要求18的方法,其中成油凝胶剂的含量为3重量%至15重量%。
20.根据权利要求19的方法,其中非极性液体的含量为88重量%至94重量%,和成油凝胶剂的含量为6重量%至12重量%。
21.根据权利要求18-20中任一项的方法,其中非极性液体是植物油、动物油或合成油。
22.根据权利要求21的方法,其中所述油是下列植物油中的一种或下列植物油的混合物:向日葵油、橄榄油、鳄梨油、杏仁油。
23.根据权利要求18和20的方法,其中非极性液体是蜡或石蜡。
24.根据权利要求1-11中任一项的成油凝胶剂用作液体中的增稠剂的用途,应用方法是将该成凝胶剂在所述液体中以一定的浓度进行使用,所述浓度低于对于所述液体和所述成油凝胶剂所给定的胶凝极限值。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004030044A DE102004030044A1 (de) | 2004-06-22 | 2004-06-22 | Triterpenhaltiger Oleogelbildner, triterpenhaltiges Oleogel und Verfahren zur Herstellung eines triterpenhaltigen Oleogels |
DE102004030044.5 | 2004-06-22 | ||
PCT/EP2005/006710 WO2005123037A1 (de) | 2004-06-22 | 2005-06-21 | Triterpenhaltiger oleogelbildner, triterpenhaltiges oleogel und verfahren zur herstellung eines triterpenhaltigen oleogels |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1972668A true CN1972668A (zh) | 2007-05-30 |
CN1972668B CN1972668B (zh) | 2013-01-09 |
Family
ID=34971468
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005800207877A Active CN1972668B (zh) | 2004-06-22 | 2005-06-21 | 含三萜的成油凝胶剂、含三萜的油凝胶和制备含三萜的油凝胶的方法 |
Country Status (30)
Country | Link |
---|---|
US (2) | US8536380B2 (zh) |
EP (1) | EP1758555B2 (zh) |
JP (1) | JP4468987B2 (zh) |
KR (1) | KR101162991B1 (zh) |
CN (1) | CN1972668B (zh) |
AT (1) | ATE423546T1 (zh) |
AU (1) | AU2005253732C1 (zh) |
BR (1) | BRPI0512288B8 (zh) |
CA (1) | CA2571606C (zh) |
CY (2) | CY1109066T1 (zh) |
DE (2) | DE102004030044A1 (zh) |
DK (1) | DK1758555T4 (zh) |
ES (1) | ES2323082T5 (zh) |
FR (1) | FR16C1003I2 (zh) |
HU (1) | HUS1600032I1 (zh) |
IL (1) | IL180057A (zh) |
LT (1) | LTC1758555I2 (zh) |
LU (1) | LU93142I2 (zh) |
MX (1) | MXPA06015233A (zh) |
NL (1) | NL300823I2 (zh) |
NO (2) | NO336747B1 (zh) |
NZ (1) | NZ552280A (zh) |
PL (1) | PL1758555T5 (zh) |
PT (1) | PT1758555E (zh) |
RS (1) | RS50832B2 (zh) |
RU (1) | RU2430717C2 (zh) |
SI (1) | SI1758555T2 (zh) |
UA (1) | UA88308C2 (zh) |
WO (1) | WO2005123037A1 (zh) |
ZA (1) | ZA200610304B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102665723A (zh) * | 2009-11-24 | 2012-09-12 | 比肯股份公司 | 含三萜的油凝胶用于伤口愈合的用途 |
CN109512780A (zh) * | 2019-01-09 | 2019-03-26 | 河南省医药科学研究院 | 一种凝胶药膏及其制备方法和应用 |
CN110402402A (zh) * | 2017-03-10 | 2019-11-01 | 科腾聚合物美国有限责任公司 | 易熔的油凝胶组合物和其制备及使用方法 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2332525A1 (en) | 2009-11-23 | 2011-06-15 | Novaliq GmbH | Pharmaceutical composition comprising propofol |
ES2537151T3 (es) | 2009-12-10 | 2015-06-02 | Neubourg Skin Care Gmbh & Co. Kg | Formulaciones de espuma estabilizadas con polímeros, libres de emulsionantes |
EP2363108B1 (de) | 2010-03-02 | 2017-08-30 | Neubourg Skin Care GmbH & Co. KG | Schaumformulierungen enthaltend mindestens ein Triterpenoid |
WO2012177825A1 (en) | 2011-06-21 | 2012-12-27 | Bvw Holding Ag | Medical device comprising boswellic acid |
EP3454663A1 (en) * | 2016-05-12 | 2019-03-20 | Rudjer Boskovic Institute | Low molecular weight organic gelators of vegetable oil |
US20190183797A1 (en) * | 2016-07-18 | 2019-06-20 | Rolf Daniels | Betulin-containing water-in-oil foams and compositions thereof |
KR20190024734A (ko) | 2017-08-31 | 2019-03-08 | (주)아모레퍼시픽 | 병풀 추출물 또는 이로부터 유래한 트리테르펜을 고함량으로 포함하는 화장료 조성물 및 이의 제조 방법 |
US12036257B2 (en) | 2017-10-31 | 2024-07-16 | Kalivir Immunotherapeutics, Inc. | Platform oncolytic vector for systemic delivery |
BR112020009867A2 (pt) | 2018-01-04 | 2020-11-03 | Amryt Research Limited | composição formadora de cremosidade |
EP3870150A1 (en) | 2018-10-26 | 2021-09-01 | Viramal Limited | Mucoadhesive gel composition |
ES2948955T3 (es) | 2018-11-30 | 2023-09-22 | Viramal Ltd | Un método de preparación de un agente gelificante, el agente gelificante obtenido de este modo y el uso de dicho agente gelificante |
GR1010072B (el) * | 2019-05-15 | 2021-09-15 | Αριστοτελειο Πανεπιστημιο Θεσσαλονικης - Ειδικος Λογαριασμος Κονδυλιων Ερευνας | Βρωσιμα κτηνιατρικα σκευασματα ενδομαστικης προστασιας θηλαστικων και μεθοδος για την παρασκευη τους |
BR112023022681A2 (pt) | 2021-04-30 | 2024-01-23 | Kalivir Immunotherapeutics Inc | Vírus oncolíticos para expressão modificada de mhc |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LU83173A1 (fr) | 1981-02-27 | 1981-06-05 | Oreal | Nouvelles compositions cosmetiques pour le traitement des cheveux et de la peau contenant une poudre resultant de la pulverisation d'au moins une plante et un agent de cohesion |
JP3363161B2 (ja) | 1991-06-27 | 2003-01-08 | ポーラ化成工業株式会社 | 非水ゲル化粧料 |
US5750578A (en) | 1997-02-11 | 1998-05-12 | Regents Of The University Of Minnesota | Use of betulin and analogs thereof to treat herpesvirus infection |
US6403816B1 (en) * | 1997-09-30 | 2002-06-11 | Dabur Research Foundation | Betulinic acid derivatives having antiangiogenic activity, processes for producing such derivatives and their use for treating tumor associated angiogenesis |
FR2779438B1 (fr) * | 1998-06-03 | 2004-12-24 | Jean Marc Aiache | Gel stable, son procede de preparation, et compositions pharmaceutiques le comprenant |
GB9908593D0 (en) | 1999-04-16 | 1999-06-09 | Quest Int | Dental compositions containing boswellia extracts |
WO2001003712A1 (en) | 1999-07-09 | 2001-01-18 | Astion Development Aps | Composition containing extracts of butyrospermum parkii and the use as medicament or dietary supplement |
ATE262283T1 (de) | 2000-02-10 | 2004-04-15 | Loders Croklaan Bv | Fettmischungen mit kristallmodifikatoren |
PT1267900E (pt) | 2000-03-28 | 2004-08-31 | Birken Gmbh | Emulsao contendo um extracto de planta contendo um triterpeno processo para a preparacao desta emulsao e para a obtencao do extracto de planta |
DE10056902A1 (de) * | 2000-11-16 | 2002-05-23 | Birken Gmbh | Verfahren zur Gewinnung von Triterpenen aus Pflanzen sowie deren Verwendung |
AU2001294953A1 (en) | 2000-09-29 | 2002-04-08 | Regents Of The University Of Minnesota | Triterpenes having fungicidal activity against yeast |
AU2001294959A1 (en) | 2000-09-29 | 2002-04-08 | Robert M. Carlson | Triterpenes having antibacterial activity |
JP2002138014A (ja) | 2000-10-31 | 2002-05-14 | Noevir Co Ltd | 微細エマルション組成物 |
DE10143964A1 (de) | 2001-09-07 | 2003-03-27 | Basf Ag | Emulgatorarme oder emulgatorfreie Systeme vom Typ Öl-in-Wasser mit einem Gehalt an Stabilisatoren und einem aminosubstituierten Hydroxybenzophenon |
DE10156297A1 (de) | 2001-11-19 | 2003-05-28 | Henkel Kgaa | Mittel zum Schutz der Haut |
JP2003335627A (ja) | 2002-03-14 | 2003-11-25 | Lion Corp | 化粧料含浸シート |
DE10237281A1 (de) | 2002-08-14 | 2004-03-04 | Birken Gmbh | Vorrichtung zur kontinuierlichen Extraktion von Extraktstoffen aus Pflanzen |
JP3779661B2 (ja) | 2002-09-13 | 2006-05-31 | 花王株式会社 | 皮膚化粧料 |
KR100489701B1 (ko) | 2002-10-09 | 2005-05-16 | 주식회사 태평양 | 고농도의 트리터페노이드를 함유하는 미소화 리포좀 및 그제조방법 |
JP2005004911A (ja) | 2003-06-13 | 2005-01-06 | Ikuta Insatsu Kk | 磁気カード |
DE10329955A1 (de) * | 2003-07-03 | 2005-02-03 | Merck Patent Gmbh | Verwendung eines hydroalkoholischen Extrakts aus Bauhinia zur Herstellung einer Zubereitung |
-
2004
- 2004-06-22 DE DE102004030044A patent/DE102004030044A1/de not_active Ceased
-
2005
- 2005-06-21 PT PT05756084T patent/PT1758555E/pt unknown
- 2005-06-21 JP JP2007517185A patent/JP4468987B2/ja active Active
- 2005-06-21 BR BRPI0512288A patent/BRPI0512288B8/pt active IP Right Grant
- 2005-06-21 KR KR1020077001575A patent/KR101162991B1/ko active IP Right Grant
- 2005-06-21 WO PCT/EP2005/006710 patent/WO2005123037A1/de active Application Filing
- 2005-06-21 MX MXPA06015233A patent/MXPA06015233A/es active IP Right Grant
- 2005-06-21 US US11/630,180 patent/US8536380B2/en active Active
- 2005-06-21 RS RS20090188A patent/RS50832B2/sr unknown
- 2005-06-21 DE DE502005006701T patent/DE502005006701D1/de active Active
- 2005-06-21 DK DK05756084.9T patent/DK1758555T4/da active
- 2005-06-21 SI SI200530657T patent/SI1758555T2/sl unknown
- 2005-06-21 ES ES05756084T patent/ES2323082T5/es active Active
- 2005-06-21 EP EP05756084A patent/EP1758555B2/de active Active
- 2005-06-21 AT AT05756084T patent/ATE423546T1/de active
- 2005-06-21 RU RU2007102084/15A patent/RU2430717C2/ru active
- 2005-06-21 PL PL05756084T patent/PL1758555T5/pl unknown
- 2005-06-21 UA UAA200700552A patent/UA88308C2/ru unknown
- 2005-06-21 CA CA2571606A patent/CA2571606C/en active Active
- 2005-06-21 CN CN2005800207877A patent/CN1972668B/zh active Active
- 2005-06-21 AU AU2005253732A patent/AU2005253732C1/en active Active
- 2005-06-21 NZ NZ552280A patent/NZ552280A/en unknown
-
2006
- 2006-12-08 ZA ZA200610304A patent/ZA200610304B/xx unknown
- 2006-12-14 IL IL180057A patent/IL180057A/en active IP Right Grant
-
2007
- 2007-01-22 NO NO20070390A patent/NO336747B1/no active Protection Beyond IP Right Term
-
2009
- 2009-05-21 CY CY20091100541T patent/CY1109066T1/el unknown
-
2013
- 2013-08-20 US US13/970,898 patent/US8828444B2/en active Active
-
2016
- 2016-07-01 NL NL300823C patent/NL300823I2/nl unknown
- 2016-07-06 LU LU93142C patent/LU93142I2/fr unknown
- 2016-07-07 LT LTPA2016023C patent/LTC1758555I2/lt unknown
- 2016-07-07 NO NO2016012C patent/NO2016012I2/no unknown
- 2016-07-11 FR FR16C1003C patent/FR16C1003I2/fr active Active
- 2016-07-11 HU HUS1600032C patent/HUS1600032I1/hu unknown
- 2016-07-12 CY CY2016025C patent/CY2016025I1/el unknown
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102665723A (zh) * | 2009-11-24 | 2012-09-12 | 比肯股份公司 | 含三萜的油凝胶用于伤口愈合的用途 |
CN102665723B (zh) * | 2009-11-24 | 2016-03-16 | 比肯股份公司 | 含三萜的油凝胶用于伤口愈合的用途 |
US9352041B2 (en) | 2009-11-24 | 2016-05-31 | Birken Ag | Use of an oleogel containing triterpene for healing wounds |
US9827214B2 (en) | 2009-11-24 | 2017-11-28 | Amryt Research Limited | Use of an oleogel containing triterpene for healing wounds |
CN110402402A (zh) * | 2017-03-10 | 2019-11-01 | 科腾聚合物美国有限责任公司 | 易熔的油凝胶组合物和其制备及使用方法 |
CN109512780A (zh) * | 2019-01-09 | 2019-03-26 | 河南省医药科学研究院 | 一种凝胶药膏及其制备方法和应用 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1972668B (zh) | 含三萜的成油凝胶剂、含三萜的油凝胶和制备含三萜的油凝胶的方法 | |
DE60225242T2 (de) | Verfahren zur herstellung von nanopartikeln | |
WO2022100642A1 (zh) | 一种用于治疗斑秃的复方外用制剂及其制备方法 | |
ID26221A (id) | Komposisi-komposisi farmasi yang dapat dijadikan gel | |
DE102005026755A1 (de) | Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung | |
CN1894158B (zh) | 使用固体脂肪作为溶剂制备纳米级或无定形颗粒的方法 | |
TWI725994B (zh) | 含有火山渣粉末粒子的多孔聚合物的複合粉體、含有其的化妝品組合物以及其製造方法 | |
JPH0710722A (ja) | 育毛剤 | |
JP3386349B2 (ja) | 水性懸濁医薬品組成物 | |
CA2275626C (en) | Homogeneous preformulations containing high concentrations of steroids, for producing low-dose solid and semi-solid pharmaceutical preparations | |
Ma et al. | Shell-formation mediated surface composition of uniform two-component microparticles fabricated by micro-fluidic spray drying: Effect of component size and solubility | |
JP2004277431A (ja) | 粒状製剤及びその製造法 | |
US3284303A (en) | Orally active progesterone compositions | |
JP2019532006A (ja) | 独特の性質を有する硫酸カルシウム半水和物の新規産生方法 | |
JPS5849607A (ja) | 硫黄粉末の微粒化方法 | |
WO2000041702A1 (fr) | Preparation steroide externe | |
CN103690476A (zh) | 微粉化硝酸芬替康唑制剂组合物及其制备方法 | |
JP2000264899A (ja) | ステロイド外用剤 | |
WO2011130877A1 (zh) | 醋丙甲泼尼龙一水合物晶型及其制备方法 | |
JPH03170430A (ja) | 有機塩基で中和したカルボン酸カフェイン誘導体を含み、かつ蜂巣炎治療に有効な局部肥満防止用組成物およびその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |